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To understand better the mediating role of ras/raf/ERK signaling pathway in development of cardiac hypertrophy and cerebrovascular events
in vivo, the molecular mechanism of the pathway in heart and cerebral arteries after isoproterenol (ISO) induced β-adrenergic receptor (βAR)
stimulation was examined in rabbit as animal model. Compared with the heart, our findings indicate that ISO-stimulation results in increase in
mRNA levels of ras, raf, and immediate-early genes in the cerebral arteries. Conversely, the ras and raf protein expression levels (determined by
Western blot) and the ras-GTP level (determined by pull-down assay) in the heart, but not the cerebral arteries, are markedly elevated after
treatment. In addition, despite constant ERK1/2 abundance, phosphorylated ERK (pERK) activity was elevated at both sites with prominent effect
on heart following stimulation. Opposing to the PKA and PKC, as upstream contributors in the pathway, which seem to be similarly affected at
both sites following ISO-stimulation, the results imply that the downstream candidates ras and raf, as well as immediate-early genes, have
different responses at both sites post-stimulation. The results provide an evidence of site-dependent differential response of ras/raf/ERK pathway
after cardiac hypertrophy-induced by ISO-stimulation. This varied response may account for underlying mechanisms of development of cardiac
hypertrophy and cerebrovascular events in heart and cerebral arteries, respectively.
© 2006 Elsevier B.V. All rights reserved.Keywords: Cardiac hypertrophy; β-adrenergic receptor; Cerebrovascular event; ras/raf/MAPK pathway1. Introduction
Although the contribution of cardiac hypertrophy as prog-
nostic clues in aggravation of cerebral damage still equivocal,
several experimental and clinical data [1–6] suggest that left
ventricular hypertrophy (LVH) is associated with cerebral
damage even in the absence of clinical symptoms. Cardiac
remodeling associated with cardiac hypertrophy involves
alterations in specific signaling molecules and their respective
downstream pathways in individual myocytes [7–9].
These hypertrophic stimuli affect the necessary alterations in
gene expression by receptor-mediated activation of downstream
kinase cascades [9,10]. Norepinephrine, as one of neurohor-
mones, has been implicated as mediators of cardiac hypertrophy⁎ Corresponding author. Tel.: +82 52 890 6727; fax: +82 51 894 5714.
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doi:10.1016/j.bbamcr.2006.08.002and failure. In cardiac hypertrophy and failure, the G-dependent
pathways activated by this neurotransmitter stimulate mitogen-
activated protein kinases (MAPK); the elusive signaling
pathway responsible for many cerebral and brain injury [11–
13]. Despite of that the common link between cardiac
hypertrophy endothelial dysfunction, MAPK activation and
cerebrovascular events still speculative [14]. Moreover, there is
possible cross-talk between the mitogen-activated protein
kinase (MAPK) and protein kinase C (PKCα) during the ISO-
induced hypertrophic response [15,16]. In addition, the target of
both protein kinase A (PKA) and PKCα is thought to be the ras/
raf/MEK/ERK cascade in a variety of cell types [17–20].
Although this diverse array of βAR stimulated interacting
cascades was shown to induce cardiac remodeling, it is not
determined yet whether chronic βAR stimulation alters genes or
proteins expression in remote vascular bed, such as the cerebral
arteries, with possible contribution in development of cere-
brovascular events [5,6].
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isoproterenol (ISO) in animals induces marked cardiac
hypertrophy within days without systolic hypertension [21–
25], making it a useful tool in experimental model. ISO interacts
with βARs of cardiomyocyte sarcolemmal membrane, leading
to the activation of different intracellular signaling pathways
[26,27]. β-Adrenergic stimulation leads to activation of many
signals that modulate the expression of proto-oncogenes, such
as c-fos, c-jun, and c-myc, with subsequent induction of cardiac
hypertrophy [28]. Previously, we provided evidence that
prolonged ISO infusion in a rabbit model leads to functional
impairment of the coronary arteries, which implies a novel
mechanism for reduced coronary reserve during cardiac
hypertrophy [29]. Since full understanding of this signaling
pathway is the first step for better intervention of βAR-induced
cardiac hypertrophy and reliable interpretation of possible
involvement in cerebrovascular events. We therefore postulate
possible central role of ras/raf/MEK/ERK cascade in the
development of both cardiac hypertrophy and cerebrovascular
events after β-adrenergic receptor (βAR) stimulation using
βAR agonist isoproterenol (ISO) in rabbit model.
This study addresses questions about the in situ local effect
of ISO-stimulation, with cardiac hypertrophy end result, on the
ras/raf/MAPK pathway in heart and its remote impact on the
cerebral arteries. The contribution of PKA and PKCα in this
cascade and the downstream activation of c-fos, c-jun, and c-
myc, as early response genes, at both sites were also tested.
2. Materials and methods
2.1. Induction of cardiac hypertrophy in an animal model
White male New Zealand rabbits (0.8–1.0 kg) were used in the study.
Cardiac hypertrophy was induced in the tested group by daily isoproterenol
administration (10 mg/kg body weight, i.v.) for 7 days [29]. The control group
was treated similarly with 0.9% saline (1 ml/kg body weight). At the end of
experimental period cardiac hypertrophy was confirmed as previously described
[29] in the tested group. Only those proved to exhibit cardiac hypertrophy were
considered in tested group. At the end of the experimental period, samples of
heart and cerebral arteries were collected. To improve the protein yield of
cerebral arteries total cerebral arteries, e.g., anterior, middle and posterior
cerebral arteries were included in the study.
2.2. PKA and PKCα assay activities
The Pep Tag assay (Promega, Madison, WI) was used to measure PKA and
total PKC activity, according to the manufacturer's instructions. Briefly, PKA
and PKC were isolated by tissue homogenization in extraction buffer A (10 mM
HEPES [pH 7.9], 10 mM KCL, 0.1 mM EDTA, 1 mM DTT, 0.5 mMTable 1
The forward and reverse primers used for quantitative real-time PCR
Gene GenBank
Accession no.
Primer sequence
Forward
H-ras X57125 5′-TGAAAGACTCGG
raf-1 NM012639 5′-ATGTCCACATGG
c-fos AB020214 5′-TCCGAGGAGCC
c-jun AB020219 5′-TTCTTGGGGCAC
c-myc AB019241 5′-TCAGAGAAGCTGphenylmethylsulfonyl fluoride (PMSF), 0.4% IGEPAL) at 4 °C using cold
Polytron homogenizer. The homogenate was then centrifuged (14,000×g) for
5 min at 4 °C. The recovered supernatant was passed through 1 ml DEAE
cellulose column that was pre-equilibrated with extraction buffer. The column
was then washed and eluted with 200 mM NaCl. In the reaction buffer, the
purified PKA and PKC samples were incubated for 30 min at 37 °C with the
specific substrate in the presence of activating solution. The reaction was
stopped in a heating block at 95 °C for 10 min. The Pep Tag assay utilizes
brightly colored, fluorescent peptides as alternative substrates that are highly
specific for the kinases in question: L-R-R-A-S-L-G peptide for PKA and P-L-S-
R-T-L-S-V-A-A-K peptide for PKC. Therefore, the activity was measured as a
function of the phosphorylation of alternative substrates used by the assay. The
PKA or PKC-induced phosphorylation specifically changes the net charge of the
fluorescent peptide substrate from +1 to −1. Consequently peptides were
separated according to their net charges via electrophoresis in 0.8% agarose
horizontal gel at 100 V for 15 min. The phosphorylated species migrated toward
the anode whilst non-phosphorylated to the cathode. The ratio between
phosphorylated to non-phosphorylated peptides was quantified using a
densitometer (Gel Doc 1000 Darkroom; Bio-Rad, Hercules, CA).
To quantify the concentration of heart PKCα soluble (cytoplasm) and
particulate (membrane) fractions, the previously frozen tissues were homo-
genized in double volume ice-cold extraction buffer A, using a liquid nitrogen
pre-cooled mortar and pestle. A handheld micro-tissue grinder was ultimately
used to homogenize the cerebral arteries. The homogenates were then
centrifuged (15,000×g) for 5 min at 4 °C. The recovered supernatant was
used to determine the soluble PKCα (cytosol) concentration. The resulting pellet
was re-suspended by stirring for 1 h at 4 °C in extraction buffer B (20 mM
HEPES [pH 7.9], 0.4 M NaCl, 1 mM EDTA, 10% glycerol, 1 mMDTT, 0.5 mM
PMSF), and re-centrifuged at 30,000×g at 4 °C. The resulting supernatant was
used to determine the particulate PKCα (membrane) concentration. Expressed
protein in each fraction was determined by Western blot using specific anti-
PKCα Ab.
2.3. Real-time quantitative PCR
Total RNA was extracted from the heart and cerebral arteries using RNA-
Bee reagent (Tel-Test; Iso-Tex Diagnostics, Houston, TX). Changes in the
mRNA levels of H-ras, raf-1, c-fos, c-jun, and c-myc were examined using
quantitative real-time PCR. After treatment with deoxyribonuclease I (Invitro-
gen, Carlsbad, CA), total RNA was reverse transcribed to cDNA using
SuperScript II reverse transcriptase (Invitrogen). Real-time quantitative PCR
was performed using the iCycler iQ system (Bio-Rad, Hercules, CA). The
primers and probes for each gene were designed using Beacon Designer 2.06
software (Premier Biosoft International, CA). All primers and probes were
designed using gene-specific sequences deposited in GenBank. The gene
expression data were normalized to mammalian GAPDH [30]. The primer
sequences used for each gene are shown in Table 1.
2.4. Western blot analysis
Twenty micrograms of protein from each tissue were immunoblotted using
antibodies against H-ras (Santa Cruz Biotechnology, Santa Cruz, CA), raf-1
(Santa Cruz Biotechnology), PKCα (Upstate Biotechnology, Lake Placid, NY),
ERK1/2 (Abcam, Cambridge, UK), phospho-ERK1/2 (Upstate Biotechnology),Reverse
ACGACGTG-3′ 5′-TCGATATAGGGGACGCCGTA-3′
TCAGCACC-3′ 5′-GGCTGAAGGTGAGGCTGATT-3′
TTTCAGTCT-3′ 5′-GCTCCCATCTCGGCATAGAA-3′
AGGAACT-3′ 5′-ACAGAGCATGACCCTGAACC-3′
GCCTCCTA-3′ 5′-TCGTTGGAGGAGAGCAGAGA-3′
Fig. 1. Effect of prolonged ISO-stimulation on PKA activity in the heart and
cerebral arteries. PKA activities of heart (A) and cerebral artery (B) showing the
time course of PKA activity following ISO infusion. Upper panels: horizontal
electrophoresis of PKA-specific non-phosphorylated and phosphorylated
substrate (Pep Tag assay) in 0.8% agarose gel. Densitometric analysis of band
intensities at each time point was determined using Multi Gauge V2.2. Lower
panels: The percentage ratio of phosphorsubstrate/non-phosphosubstrate at each
time point vs. that of the control value at day zero (100% residual activity) was
used as function of PKA activity. (Data represent the mean±SE, n=3 per group
at each time point; *P<0.05). Over time, there is a significant decrease in PKA
activity in both the heart and cerebral arteries when compared with the control
(day 0).
Fig. 2. Effect of prolonged ISO-stimulation on PKC activity (A) and PKCα
concentration (B), in heart and cerebral arteries. (A) Horizontal electrophoresis
of PKC-specific non-phosphorylated and phosphorylated substrate (Pep Tag
assay) in 0.8% agarose gel (upper panel). Densitometric analysis at each time
point was determined using Multi Gauge V2.2. Lower panel: The percentage
ratio of phosphorsubstrate/non-phosphosubstrate after ISO-stimulation vs.
control (100% residual activity) was used as direct function of PKC activity.
There was no significant change in PKC activity in either heart or cerebral
arteries following ISO-stimulation. (B) Upper panel: PKCα abundance as
determined by Western blotting for either the cytosol or membrane fractions in
heart and cerebral arteries. Lower panel: presented data as the corresponding
band intensity. It is clear that the soluble fraction of the cerebral arteries has a
marked elevation in PKCα abundance above the control value, which was
already significantly higher compared to all the other fractions. The data
represent the mean±SE of five independent experiments; *P<0.05.
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MO). Immunoreactivity was visualized with an ECL detection kit (Amersham
Biosciences, Buckinghamshire, UK).
2.5. ras activity assay
The ras activity was analyzed with a ras activation (ras pull-down) assay kit
(Upstate Biotechnology), according to the manufacturer's instructions. In brief,
each tissue extract was incubated with 15 μl of a 50% slurry of raf-1 binding
domain (RBD) conjugated with agarose beads. After extensive wash, the active
Ras protein (ras-GTP) bound by the RBD was eluted with sample buffer, and
subjected to Western blot analysis for ras. The ras-GTP levels were related to
the total ras protein levels as determined by anti-H-ras immunoblotting in the
corresponding total-cell lysates.
2.6. Determination of ERK1/2 activity
To measure the ERK1/2 activity, the concentration of phosphorylated ERK
(pERK) from tissue lysates was used as a function of ERK activity. The anti-
phospho-p44/42 ERK monoclonal antibody was used in Western blot.2.7. Statistical analysis
All results are expressed as the mean±SE. Differences between the ISO
infusion test group and the control were analyzed using an unpaired t-test. The
time course data were compared using a repeated measures one-way analysis of
variance (ANOVA). Values of P<0.05 were considered statistically significant.
3. Results
3.1. PKA and PKCα assays
The time course of PKA activity changes in the heart and
cerebral arteries after prolonged ISO infusion are shown in Fig.
1A and B, respectively. The results clearly show that the PKA
activity in both the heart and cerebral arteries decreased
gradually with time. In contrast, the PKC activity did not
change in either the heart or cerebral arteries following ISO-
stimulation (Fig. 2A). To evaluate whether any relationship
Table 2
Quantitative analysis of the relative changes in H-ras mRNA expression levels using real-time quantitative PCR during isoproterenol-induced cardiac hypertrophy
H-ras Gene CT
a ΔCT
b ΔΔCT
c Expression relative
to control d
Heart
Cardiac Hypertrophy GAPDH 12.78±0.62
H-ras 22.65±0.49 10.16±0.12 −0.31±0.19 1.24
Control GAPDH 12.01±0.31
H-ras 22.09±0.25 10.01±0.16
Cerebral arteries
Cardiac Hypertrophy GAPDH 16.87±0.78
H-ras 24.29±0.71 7.43±0.26 −0.95±0.26 1.93
Control GAPDH 14.82±0.27
H-ras 23.18±0.25 8.37±0.07
a The average of the CT data for each sample.
b The ΔCT value is calculated by the subtraction of the GAPDH CT from each sample CT.
c The ΔΔCT value is calculated by subtraction of the control ΔCT from each ISO-treated sample ΔCT.
d The expression relative to control is calculated using the equation 2−ΔΔCT.
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cytosol and membrane fractions, we determined the level of
PKCα expression. Interestingly, despite the stability of PKCα
expression in the heart cytosol and membrane fractions after
ISO-stimulation (Fig. 2B), the cerebral arteries soluble fraction
showed a significant increase after stimulation above its basal
control value. This basal value, however, was relatively higher
than other measured basal values of other fractions in heart and
cerebral arteries.
3.2. H-ras and raf-1 assay
Chronically enhanced catecholaminergic stimulation of the
myocardium has been linked to MAPK activation. To
investigate the upstreamMAPK cascade regulatory mechanism,
the H-ras and raf-1 mRNA expression level and their
corresponding protein concentration were analyzed using real-
time PCR and Western blot, respectively. We performed real-
time PCR using GAPDH as a reference housekeeping gene.
Using real-time PCR, the H-ras and raf-1 mRNA expressionTable 3
Quantitative analysis of the relative changes in raf-1 mRNA expression levels using
raf-1 Gene CT
a
Heart
Cardiac Hypertrophy GAPDH 12.86±0.73
raf-1 20.63±0.88
Control GAPDH 11.54±0.36
raf-1 19.75±0.46
Cerebral arteries
Cardiac Hypertrophy GAPDH 15.59±0.65
raf-1 21.36±0.72
Control GAPDH 14.27±0.38
raf-1 21.00±0.42
a The average of the CT data for each sample.
b The ΔCT value is calculated by the subtraction of the GAPDH CT from each sa
c The ΔΔCT value is calculated by subtraction of the control ΔCT from each ISO
d The expression relative to control is calculated using the equation 2−ΔΔCT.levels in the cerebral arteries were significantly elevated after
stimulation (Tables 2 and 3). Contrastingly, the final outcome of
this mRNA elevation was significant decrease in H-ras and raf-
1 protein levels as shown by Western blot (Fig. 3A and B) that
confirmed by decreased ras activity, demonstrated by the
lowered H-ras-GTP level (Fig. 3C). This was not the case in the
heart after ISO-stimulation, where the expressed H-ras and raf-
1 protein concentrations were markedly elevated (Fig. 3A and
B) with increased ras activity (Fig. 3C) without an initial
mRNA induction (Tables 2 and 3).
3.3. ERK1/2 and phospho-ERK1/2
The classical ERKs, ERK2 or p42 and ERK1 or p44, are
positioned downstream from raf-1 and MEK1. Together, these
comprise an orderly signaling cascade in response to a variety of
extracellular stimuli. To examine the possible ISO-evoked H-
ras and raf-1 activation, the concentration and activity of
ERK1/2 has to be determined in both heart and cerebral arteries.
Therefore, Western blot was performed using ERKs p42 andreal-time quantitative PCR during isoproterenol-induced cardiac hypertrophy
ΔCT
b ΔΔCT
c Expression relative
to control d
7.77±0.33 −0.45±0.33 1.37
8.22±0.16
5.76±0.25 −0.92±0.25 1.89
6.68±0.07
mple CT.
-treated sample ΔCT.
Fig. 3. The protein expression levels of H-ras and raf-1 (A, B), and H-ras-GTP
level in ISO-stimulated heart and cerebral arteries (C). A and B represent the
Western blot data of H-ras and raf-1 expressed proteins, respectively. (C)
Western blot of affinity-precipitated active Ras. Active Ras chemiluminescent
immunoblot data in densitometry units. The intensity was determined using
Multi Gauge V2.2. Columns represent the mean±SE, n=5 independent
experiments. □, control group;▪, ISO group. *P<0.05 compared to control.
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degree of ERK1/2 phosphorylation as a direct function of
ERK1/2 activity, immunoblotting was conducted using anti-
bodies against phospho-ERKs p42 and p44. However, ISO-
stimulation had little impact on the level of ERK1/2 expression
(Fig. 4A and B), the activity of ERK1/2 markedly increased
after ISO-stimulation (Fig. 4A and B). Note that there was a
major shift in ERK1/2 activity in the heart that increased as a
consequence of ISO-stimulation compared to the basal control
value before stimulation.
3.4. c-fos, c-jun, and c-myc mRNA
The above actions stimulate, at least in part, the translocation
of activated MAPK into the nucleus, where it phosphorylates
and thereby activates nuclear transcription factors and conse-
quently mediates transcription of the immediate-early response
oncogenes c-fos and c-jun. The mRNA levels of c-fos, c-jun,
and c-myc in heart and cerebral arteries are shown in Tables 4, 5,
and 6, respectively. However there is no change in mRNA levelof c-jun or c-myc, the level of c-fos mRNAwas increased after
prolonged ISO-stimulation in heart. In contrast, marked
increase in the mRNA levels of c-fos and c-myc mRNA
genes was observed in the cerebral arteries after prolonged
ISO-stimulation.
4. Discussion
Although the ISO-stimulated activation of the ras/raf/ERKs
pathway has been previously investigated [27,31], its detailed
role in development of cardiac hypertrophy with possible in
vivo contribution to cerebrovascular events remains unclear.
This work was done to understand better the effect of long term
ISO-stimulation with cardiac hypertrophy end result on ras/raf/
ERKs signaling pathway in both heart and cerebral arteries.
As with many Gs protein-coupled receptors, long term ISO-
stimulation of βAR receptor results in PKA-dependent receptor
phosphorylation with consequent desensitization after previous
activation [32]. Therefore there is observed decrease, rather than
increase, in PKA activity in both heart and cerebral arteries after
several days of receptor activation. Previous peaking, however,
was possibly too short to be recognized one day of ISO-
stimulation. It is not clear whether this decrease in PKA activity;
as innate inhibitor of Ras /raf pathway [33], indirectly
contributes to their activation. Moreover, recent finding
provides evidence that PKA activation pathway is unlikely
contribute to ras/raf activation pathway [34]. Ras and raf are
two proto-oncogenes that activated during hypertrophy
[27,31,35] and involve in growth modulation, cell proliferation,
and transformation. The increase in their protein expression and
activity (ras-GTP) in heart rather than cerebral arteries confirms
their site specific differential response to ISO stimulation. Their
important roles in organization of cytoskeletal proteins [36] and
modulation of actin cytoskeleton in many cell types [37] via
Rho-GTPase activation afford an explanation of their elevated
levels in heart; the place where cardiac hypertrophy occurs.
Another major finding of this study is that the mismatch on
different molecular levels, e.g. the mRNA and protein level
between ras and raf at both sites after ISO-stimulation. Since
RT-PCR technique was used to estimate the mRNA copy
numbers on transcriptional base regardless to translational, post-
translational or “translation on demand” [38] regulations level,
this discrepancy between constitutive mRNA expression and its
corresponding final protein outcome is not unlikely to be found
[39,40]. On the other hand, prenylation and subsequent
methylation are essential for posttranslational modification
events affecting many signaling regulatory proteins, therefore
ras, like many guanine nucleotide-binding proteins, is pre-
nylated and undergoes methylation [41,42]. Prenylated methy-
lated protein methyl esterase (PMPMEase) readily hydrolyzes
its protein substrate esters as a reversible and possibly
regulatory step. Since PMPMEase is recently isolated from
the rat brain [43], its presence can account for accelerated
hydrolysis of preformed, prenylated active ras in cerebral
arteries with consequent cellular autodegradation. Moreover,
the role of GTPase activating proteins that terminates ras
signaling by stimulating intrinsic GTPase activity [44] cannot
Fig. 4. Abundance and activity of ERK1/2 in the heart and cerebral arteries during isoproterenol-induced cardiac hypertrophy. (A) Whole ERK1/2 abundance in whole
extracts was measured using Western blot analysis with anti-ERK1/2 antibody using β-tubulin as house keeping reference protein. (B) The intensity of the ERK1/2
bands was determined using Multi Gauge V2.2. The columns represent the mean±SE, n=5 independent experiments. □, control groups;▪, hypertrophic groups.
*P<0.05 compared to control. (C) Phospho-ERK1/2 (as a function of activity) in whole extracts was measured using Western blot analysis with phospho-specific
ERK1/2 antibody. (D) The intensity of the phospho-ERK1/2 bands was determined using Multi Gauge V2.2. The columns represent the mean±SE, n=5 independent
experiments. □, control groups;▪, hypertrophic groups. *P<0.05 compared to control.
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reasonable explanation of the decreased activity and concentra-
tion of ras, despite of previous high mRNA expression in
cerebral arteries. These assumptions, however, remain to be
resolved.
It was proved that the effect of β-adrenoceptor activation on
ERKs activity is generally stimulatory [45,46]. In agreement
with that ERKs activation is the final stimulatory outcome
observed in both heart and cerebral arteries. Ras-GTP loading
translocates raf family mitogen-activated protein kinase
(MAPK) kinase kinases to the membrane, and initiates theTable 4
Quantitative analysis of the relative changes in c-fos mRNA expression levels using
c-fos Gene CT
a
Heart
Cardiac hypertrophy GAPDH 14.18±1.34
c-fos 23.10±1.48
Control GAPDH 13.87±1.17
c-fos 24.16±1.02
Cerebral arteries
Cardiac hypertrophy GAPDH 20.76±1.85
c-fos 27.65±1.95
Control GAPDH 13.83±0.39
c-fos 25.23±0.54
a The average of the CT data for each sample.
b The ΔCT value is calculated by the subtraction of the GAPDH CT from each sa
c The ΔΔCT value is calculated by subtraction of the control ΔCT from each ISO
d The expression relative to control is calculated using the equation 2−ΔΔCT.activation of raf, thereby activating the extracellular signal-
regulated kinase 1/2 (ERK1/2) cascade. The increased con-
centration of ras and raf as well as ras activity observed in
heart assist their consequent downstream activation of signal
transducing ERKs protein in heart rather than cerebral arteries.
Therefore, the increase in the phosphorylation rate of ERK, was
much higher in the heart, where the regulatory role of the
cytoskeleton is prominent, than in the cerebral arteries, which
may be more vulnerable to mitogenic effects.
Nevertheless, the higher basal level of pEKR in cerebral
arteries evidently exposes the constitutive role of pEKR inreal-time quantitative PCR during isoproterenol-induced cardiac hypertrophy
ΔCT
b ΔΔCT
c Expression relative
to control d
8.92±0.33 −1.35±0.33 2.55
10.27±0.35
11.40±0.28 −4.51±0.32 22.76
6.89±0.32
mple CT.
-treated sample ΔCT.
Table 5
Quantitative analysis of the relative changes in c-jun mRNA expression levels using real-time quantitative PCR during isoproterenol-induced cardiac hypertrophy
c-jun Gene CT
a ΔCT
b ΔΔCT
c Expression relative
to control d
Heart
Cardiac hypertrophy GAPDH 12.15±0.15
c-jun 22.96±0.32 10.78±0.37 0.03±0.23 0.98
Control GAPDH 13.66±1.09
c-jun 24.44±1.23 10.81±0.23
Cerebral arteries
Cardiac hypertrophy GAPDH 15.38±0.68
c-jun 22.88±0.62 11.44±0.34 −0.63±0.23 1.55
Control GAPDH 14.35±0.30
c-jun 25.79±0.58 10.81±0.23
a The average of the CT data for each sample.
b The ΔCT value is calculated by the subtraction of the GAPDH CT from each sample CT.
c The ΔΔCT value is calculated by subtraction of the control ΔCT from each ISO-treated sample ΔCT.
d The expression relative to control is calculated using the equation 2−ΔΔCT.
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compared to that of heart. Moreover, the data suggest that the
elevated pEKR level in cerebral arteries is more likely a con-
sequence of an ultimate pathway [47] rather than the conven-
tional Ras/Raf-1 activation that proved to be down regulated.
Previous data showed that PKCα is the major contributor among
PKC isoforms that involved in hypertrophic signaling in
cardiomyocytes via the ERK1/2-dependent signaling pathway
[48,49]. Regardless to ISO-stimulation, it is of interest to notice
that the basal control value of cytoplasmic PKCα, as a possible
soluble reserve of active membrane-bounded PKCα, is
comparatively higher in cerebral arteries than that of heart.
This may be attributed to tissue specificity of cerebral arteries
where the regulatory control of smooth muscle contraction takes
an advantage. Since translocation of the soluble PKCα into
membrane is the first step for its activation, therefore the
elevated level of soluble PKCα above the basal level after ISO-
stimulation has no impact on final activity of PKCα at both sites.
Further study is needed, however, to disclose the cellular benefit
behind such adaptation in cerebral arteries.Table 6
Quantitative analysis of the relative changes in c-myc mRNA expression levels usin
c-myc Gene CT
a
Heart
Cardiac hypertrophy GAPDH 12.03±0.15
c-myc 24.40±0.20
Control GAPDH 12.09±0.34
c-myc 24.06±0.47
Cerebral artery
Cardiac hypertrophy GAPDH 15.06±0.35
c-myc 25.74±0.53
Control GAPDH 13.97±0.28
c-myc 27.35±0.38
a The average of the CT data for each sample.
b The ΔCT value is calculated by the subtraction of the GAPDH CT from each sa
c The ΔΔCT value is calculated by subtraction of the control ΔCT from each ISO
d The expression relative to control is calculated using the equation 2−ΔΔCT.Immediate-early genes (IEGs; also known as primary (early)
response genes) constitute a superfamily of inducible proto-
oncogenes, many of which encode nuclear transcription factors
that activate the promoters of target genes involved in regulating
neuronal function, adaptive processes, or apoptotic cell death
[50–53]. As final outcome of increased phosphorylation rate of
ERK after βAR stimulation, there is an increase in mRNA
levels of fos and c-myc (as early response genes) in the cerebral
arteries and c-fos in heart. The increased level of expression of
early response genes in cerebral arteries evidently supports their
potential phenotypic alteration following ISO-stimulation. The
consequent development of cerebrovascular events, however,
has not proved in our results.
Although it is known that myocardial hypertrophy is not a
prerequisite for changes in IEGs expression in vivo [54], it is
clear that there is a participation of complex regulatory
machinery that controls the overall end result in the form of
the activation of IEGs. Considering the stimulatory effect of β-
Adrenoceptor on PI3 kinase activity, which is Gi-dependent and
generally cell growth stimulatory [55], it is not surprising thatg real-time quantitative PCR during isoproterenol-induced cardiac hypertrophy
ΔCT
b ΔΔCT
c Expression relative
to control d
12.37±0.29 0.4±0.29 0.76
11.97±0.45
13.37±0.32 −2.7±0.48 6.50
10.68±0.48
mple CT.
-treated sample ΔCT.
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contribute to fos and c-myc genes activation.
In conclusion the increased concentration and activity of ras
and raf in heart with consequent downstream pERK elevation
reflect the importance of ras/raf/ERK signaling pathway during
ISO-stimulation with cardiac hypertrophy end-result. The
decrease in their concentration in cerebral arteries, however,
clearly disproves their local impact on ERK activation with
possible contribution of ultimate regulators. These data give the
first insight about site-specific diversity of ras/raf/ERK
signaling pathway as consequence of ISO-stimulation.
Increased expression of IEGs in cerebral arteries raises the
speculation of ISO-stimulation involvement in cerebrovascular
events that warrants further investigation to elucidate the exact
mechanism. The mismatch noticed between mRNA transcrip-
tion level and its final protein outcome suggests post-translation
multidisciplinary fine tuning that leads to this discrepancy.
From the study attention should be taken to the local final
outcome rather than remote intermediate results for better
addressing pathophysiological interpretation on molecular
basis.
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